<SEC-DOCUMENT>0001171843-26-004524.txt : 20260708
<SEC-HEADER>0001171843-26-004524.hdr.sgml : 20260708
<ACCEPTANCE-DATETIME>20260708060504
ACCESSION NUMBER:		0001171843-26-004524
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260708
FILED AS OF DATE:		20260708
DATE AS OF CHANGE:		20260708

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Addex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001574232
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39179
		FILM NUMBER:		261160718

	BUSINESS ADDRESS:	
		STREET 1:		CHEMIN DES MINES 9
		CITY:			GENEVA
		STATE:			V8
		ZIP:			CH-1202
		BUSINESS PHONE:		01141228841555

	MAIL ADDRESS:	
		STREET 1:		CHEMIN DES MINES 9
		CITY:			GENEVA
		STATE:			V8
		ZIP:			CH-1202
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_070826.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>For the month of July 2026</strong></p><p style="text-align: center;">Commission File Number: <strong>001-39179</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Addex Therapeutics Ltd</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>Chemin des Mines 9,<br /> CH-1202 Geneva,<br /> Switzerland<!--Chemin des Mines 9,<br> CH-1202 Geneva,--></strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<br />Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]<br /><br /></p><hr style="page-break-after: always;" noshade="noshade" /><!--<p> <p>On July 8, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br /><br /><a href="exh_991.htm">(c) Exhibit 99.1. Press release dated July 8, 2026</a></p><p style="text-align: center;"><strong>INCORPORATION BY REFERENCE</strong></p><p>Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-291644) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.&#160;</p><p style="text-align: center;"><strong>RISK FACTORS</strong>&#160;</p><p>Our business faces significant risks. You should carefully consider all of the information set forth in this Report on Form&#160;6-K and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors related to our business set forth in&#160;our Annual Report on Form&#160;20-F for the year ended December&#160;31, 2025&#160;filed with the Securities and Exchange Commission on May 15, 2026. Our business, financial condition, results of operations and growth prospects could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of&#160;certain factors including the risks described in our Annual Report and our other SEC filings.</p></p><p></p>--><p style="box-sizing: border-box; margin: 0px 0px 0.625em; color: #363636; font-family: 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; font-size: 14px;">&#160;<p>On July 8, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br /><br /><a href="exh_991.htm">(c) Exhibit 99.1. Press release dated July 8, 2026</a></p><p style="text-align: center;"><strong>INCORPORATION BY REFERENCE</strong></p><p>Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-291644) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.&#160;</p><p style="text-align: center;"><strong>RISK FACTORS</strong>&#160;</p><p>Our business faces significant risks. You should carefully consider all of the information set forth in this Report on Form&#160;6-K and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors related to our business set forth in&#160;our Annual Report on Form&#160;20-F for the year ended December&#160;31, 2025&#160;filed with the Securities and Exchange Commission on May 15, 2026. Our business, financial condition, results of operations and growth prospects could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of&#160;certain factors including the risks described in our Annual Report and our other SEC filings.</p>&#160;<p style="box-sizing: border-box; margin: 0px 0px 0.625em; color: #363636; font-family: 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; font-size: 14px;"></p><hr style="break-after: page;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURE</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%"><strong>&#160;&#160;&#160;&#160;Addex Therapeutics Ltd&#160;&#160;&#160;&#160;</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: July 8, 2026</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%">&#160;&#160;&#160;&#160;/s/ Tim Dyer&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Tim Dyer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Chief Executive Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr></table><p><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><font style="font-size: 10pt;"><strong>EXHIBIT INDEX</strong></font><font style="font-size: 10pt;">&#160;</font></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Exhibit Number</strong></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Description</strong></font></td></tr><tr><td>&#160;</td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td style="vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_991.htm">Press release dated July 8, 2026</a> </font></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML lang="en-US"><HEAD><TITLE>EdgarFiling</TITLE>
<META content="text/html; charset=windows-1252" >
<META name="GENERATOR" content="MSHTML 8.00.7601.18094" ></HEAD>
<BODY>
<P><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><strong>Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness</strong></p><p style="text-align: center;"></p><p>
 <p><b>Ad Hoc Announcement Pursuant to Art.&#8239;53 LR</b>&#160;</p>  <p align="justify"><b>Geneva, Switzerland, July 8, 2026</b> <b>-</b> <u>Addex Therapeutics</u> (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the <i>International Journal of Neuropsychopharmacology</i>, expands the growing body of evidence supporting mGlu7 as an important mechanism regulating key brain functions and a promising therapeutic target across a range of central nervous system disorders, including mood disorders, anxiety disorders, post-traumatic stress disorder (PTSD), and other conditions associated with dysregulated stress responses.</p>  <p align="justify">"This publication demonstrating the role of mGlu7 modulation in sleep and wakefulness adds another important piece of evidence supporting the therapeutic potential of targeting these receptors with allosteric modulation," said Tim Dyer, CEO at Addex. "ADX71743 has consistently helped establish the biological role of mGlu7 across multiple disease-relevant models, and we are pleased to see this body of work continue to strengthen the scientific rationale for Neurosterix's ongoing development of this exciting target."</p>  <p align="justify">In the study, ADX71743 increased wakefulness while reducing both REM and non-REM sleep in rats. The compound also altered stress-induced changes in key neurotransmitters, including glutamate, GABA and monoamines, across multiple brain regions in awake animals, producing neurochemical effects consistent with modulation of stress-responsive neural circuits. Together, these findings further validate the pharmacological profile of selective mGlu7 inhibition in vivo and provide additional support for the therapeutic potential of this novel mechanism.</p>  <p align="justify">Previous studies have demonstrated that selective mGlu7 inhibition can modulate anxiety-related behaviours, disrupt maladaptive fear memory reconsolidation and influence glutamatergic signalling in both rodent and human brain tissue.</p>  <p align="justify"><b>About ADX71743</b><br >ADX71743 is a potent, selective, brain-penetrant negative allosteric modulator of metabotropic glutamate receptor 7 (mGlu7). The compound has served as the prototype molecule underpinning numerous publications investigating the therapeutic potential of mGlu7 modulation across anxiety, stress-related disorders, sleep regulation, fear memory and visceral pain. ADX71743 was discovered by Addex and now forms part of the mGlu7 program being advanced by Neurosterix, the neuroscience company launched by Addex and Perceptive Advisors in 2024.</p>  <p><b>About Addex Therapeutics</b></p>  <p align="justify">Addex Therapeutics&#160;s a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders.&#160;Addex's&#160;lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery.&#160;Addex's&#160;partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies.&#160;Addex&#160;is advancing an independent GABAB PAM program for chronic cough.&#160;Addex&#160;holds a 20% equity interest in a private spin out company,&#160;Neurosterix&#160;US Holdings&#160;LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia,&#160;psychosis&#160;and mood-related disorders&#160;and&#160;mGlu7 NAM for mood disorders.&#160;In addition,&#160;Addex&#160;has invested in&#160;Stalicla,&#160;a private Swiss&#160;company pioneering a&#160;precision medicine approach for neurodevelopmental and neuropsychiatric disorders.&#160;&#160;</p>  <p align="justify">Addex&#160;shares are listed on the SIX Swiss Exchange and American Depositary Shares&#160;representing&#160;its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange. For more information, visit&#160;www.addextherapeutics.com.</p>  <p><b>Contacts:</b></p> <table style="width:377pt; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="width:264.87px;;vertical-align: top ; ">Tim Dyer<br >Chief Executive Officer<br >Telephone: +41 22 884 15 55 <br ><u>PR@addextherapeutics.com</u> </td><td style="width:237.8px;;vertical-align: top ; ">Mike Sinclair<br >Partner, Halsin Partners<br >+44 (0)7968 022075<br ><u>msinclair@halsin.com</u> </td></tr></table> <p align="justify"><b>Addex Forward Looking Statements:</b></p>  <p align="justify">This press release&#160;contains&#160;forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in&#160;Addex&#160;Therapeutics' Annual Report on Form 20-F,&#160;prospectus&#160;and other filings that&#160;Addex&#160;Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent&#160;Addex&#160;Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any&#160;subsequent&#160;date.&#160;Addex&#160;Therapeutics explicitly&#160;disclaims&#160;any obligation to update any forward-looking statements.&#160;</p> <p></p>
</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
